BridgeBio Financial Statements From 2010 to 2026
| BBIO Stock | USD 75.25 0.81 1.06% |
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 44.1959 | Revenue |
BridgeBio Pharma Total Revenue |
|
Check BridgeBio Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio Pharma's main balance sheet or income statement drivers, such as Interest Income of 20.8 M, Depreciation And Amortization of 3.9 M or Interest Expense of 119.9 M, as well as many indicators such as Price To Sales Ratio of 25.14, Dividend Yield of 4.0E-4 or Days Sales Outstanding of 8.49. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Pharma Valuation or Volatility modules.
BridgeBio | Select Account or Indicator | Build AI portfolio with BridgeBio Stock |
BridgeBio Pharma Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BridgeBio Pharma Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BridgeBio Pharma Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BridgeBio Pharma Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BridgeBio Fundamental Market Drivers
BridgeBio Upcoming Events
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
About BridgeBio Pharma Financial Statements
BridgeBio Pharma investors utilize fundamental indicators, such as revenue or net income, to predict how BridgeBio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 13.1 M | 21.8 M | |
| Total Revenue | 255.2 M | 267.9 M | |
| Cost Of Revenue | 4.5 M | 2.9 M | |
| Stock Based Compensation To Revenue | 0.50 | 0.47 | |
| Sales General And Administrative To Revenue | 15.89 | 7.99 | |
| Research And Ddevelopement To Revenue | 2.05 | 1.95 | |
| Revenue Per Share | 1.07 | 1.13 | |
| Ebit Per Revenue | (3.07) | (3.23) |
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against BridgeBio Stock
| 0.54 | ABNX | Abionyx Pharma SA | PairCorr |
| 0.53 | OSE | OSE Pharma SA | PairCorr |
| 0.48 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.42 | VCEL | Vericel Corp Ord | PairCorr |
| 0.41 | OB3 | OPTIBIOTIX HLTH PLC | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of BridgeBio Pharma Correlation against competitors. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Will Biotechnology sector continue expanding? Could BridgeBio diversify its offerings? Factors like these will boost the valuation of BridgeBio Pharma. Projected growth potential of BridgeBio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BridgeBio Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.21) | Revenue Per Share | Quarterly Revenue Growth 43.18 | Return On Assets | Return On Equity |
BridgeBio Pharma's market price often diverges from its book value, the accounting figure shown on BridgeBio's balance sheet. Smart investors calculate BridgeBio Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since BridgeBio Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between BridgeBio Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BridgeBio Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.